Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671814 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults
A Phase 1 study, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00671814 is a Phase 1 study that has completed, run by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 80 participants.
The verdict
NCT00671814, a Phase 1 study, has completed, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single rising oral doses and multiple oral doses of TR-701
Interventions
- DRUG placebo
- DRUG linezolid
- DRUG TR-701
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2008-01-06 |
| Est. Completion | 2008-06-06 |
| Phase | Phase 1 |
Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)18 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00671814
The ClinicalTrials.gov registry entry for NCT00671814 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00671814 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00671814 about?
NCT00671814 is a clinical study titled "Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single rising oral doses and multiple oral doses of TR-701
What is the current status of trial NCT00671814?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2008-01-06. Estimated completion is 2008-06-06.
What interventions are being tested in trial NCT00671814?
The interventions under investigation include: placebo (DRUG), linezolid (DRUG), TR-701 (DRUG).
Who is sponsoring clinical trial NCT00671814?
This trial is sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.